Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD | Market Cap | 21.52M -13.5% |
| Revenue (ttm) | 3.00M -90.8% |
| Net Income | -6.11M |
| EPS | -2.26 |
| Shares Out | 2.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 311 |
| Open | 7.74 |
| Previous Close | 7.50 |
| Day's Range | 7.74 - 7.74 |
| 52-Week Range | 5.10 - 15.00 |
| Beta | 1.14 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 26, 2026 |
About Devonian Health Group
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermati... [Read more]
Financial Performance
In fiscal year 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.
Financial StatementsNews
Devonian Health Group Receives Health Canada Authorization to Evaluate Novel Thykamine™ Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients
New proprietary Thykamine™ 0.1% formulation expands Devonian's clinical development program into supportive oncology, with a potential differentiated regulatory pathway. KEY HIGHLIGHTS Significant cli...
Devonian Health Group Provides Update on its Planned NYSE American Listing
QUEBEC CITY, Oct. 16, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) today provides an update on its proposed listing on the NYSE American in ...
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
QUEBEC, Sept. 11, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offerin...
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
Validated HPLC-MS, NMR and a validated cell-based biological potency assay using the U937 human cell line, with MIP-1β as a biological marker of Thykamine™'s anti-inflammatory activity, provide comple...
Devonian Health Group Anticipates to Commence Trading on the NYSE American
QUEBEC, Aug. 18, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering...
Devonian Health Group Slides: Investor presentation
Devonian Health Group has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative t...
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatm...
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
(all amounts are in Canadian dollars) Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per ...
Devonian Health Group Report: Q3 2026
Devonian Health Group published a report on June 29, 2026 containing material business information for investors and shareholders.
Devonian Health Group MD&A: Q3 2026
Devonian Health Group filed a regulatory document on June 29, 2026 disclosing important business information.
Devonian Health Group Earnings release: Q3 2026
Devonian Health Group released its Q3 2026 earnings on June 29, 2026, summarizing the period's financial results.
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
QUÉBEC, March 30, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative t...
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
(all amounts are in Canadian dollars) Quarter ended January 31, 2026, net loss of $2.2 million dollars, ($0.81) per share Six months ended January 31, 2026, net loss of $3.8 million dollars, ($1.37) p...
Devonian Health Group Earnings release: Q2 2026
Devonian Health Group released its Q2 2026 earnings on March 25, 2026, summarizing the period's financial results.
Devonian Health Group MD&A: Q2 2026
Devonian Health Group filed a regulatory document on March 25, 2026 disclosing important business information.
Devonian Health Group Report: Q2 2026
Devonian Health Group published a report on March 25, 2026 containing material business information for investors and shareholders.
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Th...
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
QUEBEC, Feb. 17, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed...
Devonian reports additional molecular data from MASH liver study
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire...
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to t...
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
QUÉBEC, Feb. 2, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinf...
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
QUÉBEC, Jan. 20, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that, in connection with an evaluation of an additional ...
Devonian Health Group Announces Grant of Stock Options
QUEBEC , Dec. 19, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription d...
Devonian Health Group MD&A: Q1 2026
Devonian Health Group filed a regulatory document on December 11, 2025 disclosing important business information.